Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice
Open accessThe DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long-term complications of diabetes, a significant proportion of PwD are not attaining their glycemic goals. During the past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials and real-world studies have shown that the use of AID systems is safe and effective in helping PwD achieve their long-term glycemic goals while reducing hypoglycemia risk. Thus, AID systems have recently become an integral part of diabetes management. However, recommendations for using AID systems in clinical settings have been lacking. Such guided recommendations are critical for AID success and acceptance. All clinicians working with PwD need to become familiar with the available systems in order to eliminate disparities in diabetes quality of care. This report provides much-needed guidance for clinicians who are interested in utilizing AIDs and presents a comprehensive listing of the evidence payers should consider when determining eligibility criteria for AID insurance coverage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent consensus recommendations suggest starting hypoglycemia treatment with 5 to 10 g of simple carbohydrates for automated insulin delivery systems where insulin pump algorithms integrate real-time data from continuous glucose monitors [28].”
From Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus (2026) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are separate consensus recommendations for people using automated insulin delivery who experience a hypoglycemia caused by exercise or excessive bolus of rapid-acting insulin [28].”
From Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus (2026) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“By 2023, six out of these proposed algorithms advanced to systems accepted in the clinical practice: Medtronic 670G/770G, Medtronic 780G, CamAPS FX developed in Cambridge, UK, the French system Diabeloop, Tandem's Control-IQ, and Insulet's Omnipod 5. 112”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Self-citationInternational consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citationUpdated Guidance on the Reporting of Race and Ethnicity in Medical and Science Journals
Flanagin, A., Frey, T., Christiansen, S. L., & AMA Manual of Style Committee (2021) · JAMA · doi:10.1001/jama.2021.13304 · Cited by 1,615
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Self-citationHolt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Self-citationSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citation
Research works printed but not linked: 1
- 28. Ware J, Allen JM, Boughton CK, et al. Randomized trial of closedloop control in very young children with type 1 diabetes. N Engl J Med. 2022; 386 (3):209-219.
Cited by
Items 101–200 of 443
Hybrid Control Policy for Artificial Pancreas via Ensemble Deep Reinforcement Learning
Lv, W., Wu, T., Xiong, L., Wu, L., Zhou, J., Tang, Y. S., & Qian, F. (2024) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2024.3451712 · Cited by 17
“Of these approaches, PID and MPC are the most widely used and have been leveraged for commercial AP systems in real life [17].”
Tanenbaum, M. L., COMMISSARIAT, P. V., Wilmot, E. G., & Lange, K. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241275963 · Cited by 15
“5 Furthermore, qualitative work has identified the need for training, mentorship, expert advice, and access to 24-hour technical support to upskill HCPs with less familiarity with the technology.”
Self-citation(Hybrid) Closed-Loop Systems: From Announced to Unannounced Exercise
Zimmer, R. T., Auth, A., Schierbauer, J., Haupt, S., Wachsmuth, N. B., Zimmermann, P., Voit, T., Battelino, T., Sourij, H., & Moser, O. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0293 · Cited by 19
Self-citationDiabetes Technology in People with Type 2 Diabetes: Novel Indications
Agarwal, S., Galindo, R. J., Shah, A. V., & Abreu, M. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01536-4 · Cited by 12
Brixner, D. I., Edelman, S. V., Sieradzan, R., & Gavin, J. R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01598-3 · Cited by 16
“This can affect the accuracy of insulin delivery [42].”
BackgroundDekker, P., van den Heuvel, T. R. A., Arrieta, A., Castañeda, J., Mul, D., Veeze, H. J., Cohen, O., & Aanstoot, H. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241290259 · Cited by 17
Hughes, M. S., Pasquel, F. J., Davis, G. M., Lal, R., Buckingham, B. A., Boughton, C. K., Brown, S. A., & Bally, L. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0343 · Cited by 14
Self-citationStamati, A., & Christoforidis, A. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02446-x · Cited by 16
“Within this landscape, Automated insulin delivery (AID) systems have emerged as notable innovations, with the potential to revolutionize diabetes management, particularly in populations such as pregnant women with T1DM [ 7 , 8 ].”
Fisker, S., Christensen, M., Bach, E., Bibby, B. M., & Hansen, K. W. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70043 · Cited by 14
“Insulin pumps with automated insulin delivery (AID) have profoundly changed the glycaemic treatment of type 1 diabetes [1–4].”
The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus
Giorgino, F., Battelino, T., Bergenstal, R. M., Forst, T. M., Green, J. B., Mathieu, C., Rodbard, H. W., Schnell, O., & Wilmot, E. G. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231204584 · Cited by 20
“45 Regarding T2D, URAA are currently not explicitly addressed in guidelines and recommendations by medical societies such as the ADA and EASD in their current 2022 Consensus Report on Management of Hyperglycemia in Type 2 Diabetes.”
Self-citationAI-Driven Management of Type 2 Diabetes in China: Opportunities and Challenges
He, Z., & Li, W. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s495364 · Cited by 13
Lee, T., Collett, C., Bergford, S., Hartnell, S., SCOTT, E. M., Lindsay, R. S., Hunt, K. F., McCance, D. R., Barnard-Kelly, K. D., Rankin, D., et al. (2024) · Efficacy and Mechanism Evaluation · doi:10.3310/wchz4201 · Cited by 20
Self-citationTeixeira, T., Godoi, A., Romeiro, P. H. C. L., Novaes, J. V. L. C., Faria, F. M. D. F., Pereira, S. F., & Lamounier, R. N. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02284-3 · Cited by 13
“Several studies have demonstrated therapeutic benefits of AID systems in non-pregnant populations with T1DM [11].”
Barnard-Kelly, K. D., Gonder-Frederick, L. A., Weissberg-Benchell, J. A., & Wisk, L. E. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241276550 · Cited by 12
“Currently, the systems differ 44 with respect to the hardware (the pump and the CGM system that is used), the alarm burden, the degree of user input required for system functioning, the ability of the user to adjust the algorithm, and the ability of the system to compensate for changes in work/life…”
Self-citationZhou, Y., Boucsein, A., Michaels, V. R., Gray, M. K., Jefferies, C., Wiltshire, E. J., Paul, R. G., Parry‐Strong, A., Pasha, M., Petrovski, G., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16210 · Cited by 11
Johansson, M. M. E., de Ribot, F. M., Sime, M.-J., Boucsein, A., Zhou, Y., Jefferies, C., Paul, R. G., Wiltshire, E. J., Abraham, M. B., Jones, T. W., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0568 · Cited by 12
“…and without pre-existing DR may suggest that additional long-term bene fi ts can be gained by initiating AID therapy as soon as possible once a diagnosis of diabetes has been established, 33 as recommended by current International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines.”
Saboo, B., Garg, S. K., Bergenstal, R. M., Battelino, T., Ceriello, A., Choudhary, P., de Bock, M. I., Elbarbary, N. S., Forlenza, G. P., Gómez, A. M., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0028 · Cited by 12
Self-citationSimonson, G. D., Criego, A. B., Battelino, T., Carlson, A. L., Choudhary, P., Franc, S., Gershenoff, D. C., Grunberger, G., Hirsch, I. B., Isaacs, D. M., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0107 · Cited by 11
Self-citationKovatchev, B. P., & Lobo, B. J. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0117 · Cited by 10
“…consensus on the use of CGM. 21 The AGP report is now adopted by many CGM device manufacturers in their CGM companion software, and is proposed by international consensuses as a standardized output in the evaluation of AID technologies, 22 and the presentation of results from clinical trials.”
Self-citationDo, Q. D., Hašková, A., Radovnická, L., Konečná, J., Horová, E., Parkin, C. G., Grunberger, G., Prázný, M., & Šoupal, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15289 · Cited by 10
Self-citationBoucsein, A., Zhou, Y., Haszard, J. J., Jefferies, C., Wiltshire, E. J., Styles, S. E., Crocket, H. R., Galland, B. C., Pasha, M., Petrovski, G., et al. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01397-4 · Cited by 10
“Several commercial AHCL systems are currently available and are defined by their ability to not only modulate basal insulin delivery but also provide varying degrees of automated boluses to correct high glucose levels [6].”
BackgroundJalilova, A., Pilan, B. Ş., Demir, G., Özbaran, B., Balkı, H. G., Arslan, E., Köse, S., Özen, S., Darcan, Ş., & Gökşen, D. (2024) · European Journal of Pediatrics · doi:10.1007/s00431-024-05551-1 · Cited by 15
Adolfsson, P., Heringhaus, A., Sjunnesson, K., Mehkri, L., & Bolin, K. (2024) · Diabetic Medicine · doi:10.1111/dme.15432 · Cited by 10
Nimri, R., & Phillip, M. (2025) · Hormone Research in Paediatrics · doi:10.1159/000543654 · Cited by 15
“However, a training plan is essential, which is tailored to the individual, and comprehensive education should be provided prior to AID initiation [22].”
InfluentialSelf-citationFully automated insulin delivery systems in type 1 diabetes: A systematic review and meta‐analysis
Fan, W., Deng, C., Xu, R., Liu, Z., He, Y., Zhou, Z., & Li, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16499 · Cited by 12
“16,28 Given the characteristics of qualitative meal announcements without carbohydrate counting, such as ‘ usual for me, more or less ’ , and making all dose decisions and delivering insulin autonomously, we classified AID systems with qualitative meal announcements as fully AID systems for pooled…”
Chien, A., Shin, J., Liu, M., Arrieta, A., Cordero, T. L., Swensen, A. R., & Vigersky, R. A. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251376654 · Cited by 11
“Diabetes technology has been used mainly in T1D and is a recommended therapy in the majority of guidelines, 9,33,34 but a growing body of evidence of AID use in T2D is emerging.”
Newman, C., Hartnell, S., Wilinska, M. E., Alwan, H., & Hovorka, R. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231187915 · Cited by 12
“1,7 8-15 Rates of level 1 hypoglycemia varied between studies and tended to be higher in studies with younger participants.”
Self-citationA Diabetes Pregnancy Technology Roadmap: The 2023 Norbert Freinkel Award Lecture
Murphy, H. R. (2024) · Diabetes Care · doi:10.2337/dci23-0067 · Cited by 12
Self-citationConstrained Versus Unconstrained Model Predictive Control for Artificial Pancreas
Toffanin, C., & Magni, L. (2023) · IEEE Transactions on Control Systems Technology · doi:10.1109/tcst.2023.3291564 · Cited by 11
Ferreira, R. O. M., Trevisan, T., Pasqualotto, E., Schmidt, P., Pedrotti, M., Watanabe, J. M. F., & van de Sande‐Lee, S. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0280 · Cited by 16
“Finally, the absence of data re-lated to costs precluded the assessment of this barrier, which is one of the significant challenges associated with access to diabetes technology (44,45).”
BackgroundHirsch, I. B., Parkin, C. G., Cavaiola, T. S., & Bergenstal, R. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15883 · Cited by 8
“The next example involves a 64-year-old male with a 9-year duration of T2D, BMI 30 kg/m 82 Patients who use an AID system, depending on the type of pump, can achieve the same effect by raising their upper glucose target threshold, announce a ‘ less than usual ’ meal size, or switch to the ‘…”
Self-citationMoser, O., Zaharieva, D. P., Adolfsson, P., Battelino, T., Bracken, R. M., Buckingham, B. A., Danne, T., Davis, E. A., Dovč, K., Forlenza, G. P., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000542287 · Cited by 15
Self-citationHenske, J. A., Albashaireh, A., Turner, L. V., Beach, G., & Riddell, M. C. (2025) · Clinical Diabetes · doi:10.2337/cd24-0100 · Cited by 9
“…administer a correction bolus ( 25% of the usual correction 31%, 26 – 50% of the usual correction 31%, 51 – 75% of the usual correction 11%, and > 75% of the usual correction 6%), which again would be considered appropriate on some, but not all, occasions, according to guidelines (3,4,21,22).”
InfluentialSelf-citationMolfetta, S. D., Rossi, A., Assaloni, R., Franceschi, R., Grancini, V., Guardasole, V., Scaramuzza, A. E., Scarpitta, A. M., Trombetta, M., Zanfardino, A., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112117 · Cited by 13
Tumminia, A., Santoro, G. M., Oteri, V., Galeano, F., Baratta, R., Gullo, D., Frittitta, L., Sciacca, L., Moli, R. L., Piticchio, T., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112173 · Cited by 9
New therapies towards a better glycemic control in youths with type 1 diabetes
Cardona‐Hernandez, R., Dovč, K., Biester, T., Ekhlaspour, L., Macedoni, M., Tauschmann, M., & Mameli, C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106882 · Cited by 15
Self-citationA Nutritional Approach to Optimizing Pump Therapy in Type 1 Diabetes Mellitus
Gitsi, E., Livadas, S., Angelopoulos, N., Paparodis, R. D., Raftopoulou, M., & Argyrakopoulou, G. (2023) · Nutrients · doi:10.3390/nu15234897 · Cited by 13
“Given the current limitations of CGM and Artificial Intelligence (AI), T1DM nutrition education should prioritize carbohydrate counting over ICR calculation [99,100].”
Dalla Libera, A., Toffanin, C., Drecogna, M., Galderisi, A., Pillonetto, G., & Cobelli, C. (2023) · APL Bioengineering · doi:10.1063/5.0145446 · Cited by 8
Self-citationPemberton, J. S., Collins, L., Drummond, L., Dias, R. P., Krone, R. E., Kershaw, M., & Uday, S. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004045 · Cited by 8
“The content of these resources was taken from the Advanced Technologies and Treatments for Diabetes (ATTD) consensus on AID technologies 29 and the UK’s Diabetes Technology Network Best Practice Guidelines.”
MethodFiska, V., Papanikolaou, E., Patila, M., Prodromidis, M. I., Trachioti, M. G., Tzianni, Ε. I., Spyrou, K., Angelidis, P. A., & Tsipouras, M. G. (2024) · Micromachines · doi:10.3390/mi15070887 · Cited by 10
“These systems utilize a combination of GM technology and automated insulin delivery (AID) systems to regulate blood glucose levels [29,30].”
Excellence in the management of Advanced Hybrid Closed-Loop Systems: Lessons from the Polish cohort
Matejko, B., van den Heuvel, T. R. A., Castañeda, J., Arrieta, A., CYRANKA, K. M., Cohen, O., Małecki, M., & Klupa, T. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111832 · Cited by 11
Zhou, Y., Lei, M., Yang, D., Ling, P., Ni, Y., Deng, H., Xu, W., Yang, X., Wheeler, B. J., Weng, J., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111910 · Cited by 10
Wu, Z., Lebbar, M., Bonhoure, A., Raffray, M., Devaux, M., Grou, C., Messier, V., Boudreau, V., Vanasse, A., Brazeau, A., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0561 · Cited by 9
Closed-loop therapy: recent advancements and potential predictors of glycemic outcomes
Royston, C., Hovorka, R., & Boughton, C. K. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2492363 · Cited by 12
“Hybrid closed-loop systems have become the standard of clinical care to manage T1D as they increase time in range (70 to 180 mg/dL) without increasing hypoglycemia while also reducing the burden of care [3–5].”
InfluentialSelf-citationEvolution of the Artificial Pancreas: Components and Integration—CGMs, Insulin, and AP Systems
Bergenstal, R. M., Heller, A., Breton, M. D., Vigersky, R. A., Brown, S. A., Forlenza, G. P., Sherr, J. L., Hovorka, R., Russell, S. J., Damiano, E. R., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251342239 · Cited by 10
Self-citationOktavian, P., Wungu, C. D. K., Amin, I. M., & Wibisono, S. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag133 · Cited by 8
Degen, I., Brown, K. R., Reeve, H. W. J., & Abdallah, Z. S. (2024) · JMIRx Med · doi:10.2196/44384 · Cited by 9
Open-source automated insulin delivery in type 1 diabetes—the evidence is out there
Hussain, S., Lal, R., & Braune, K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00283-2 · Cited by 9
Self-citationRefining Insulin on Board with netIOB for Automated Insulin Delivery
Riddell, M. C., Lewis, D. M., Turner, L. V., Lal, R., Shahid, A., & Zaharieva, D. P. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241267820 · Cited by 7
“9,10 These factors, which are often perplexing and unpredictable to persons living with T1D, still present significant challenges for the self-management of diabetes using current AID systems.”
Self-citationAngelino, S., Longo, M., Caruso, P., Scappaticcio, L., Martino, N. D., Lorenzo, C. D., Forestiere, D., Paglionico, V. A., Bellastella, G., Maiorino, M. I., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111859 · Cited by 6
Oser, S. M., Putman, M. S., Russell, S. J., Westfeldt, E. B., Huss, K. B., Prince, B. K., Parascando, J. A., O’Connor, M. Y., Sabean, A., Ashley, A. L., et al. (2025) · Clinical Diabetes · doi:10.2337/cd24-0104 · Cited by 8
“AID systems must be available and sup-portable through primary care clinics, or existing disparities in access to technology (17 – 19) will widen between those seeing subspecialists and those seeing primary care providers (PCPs), including people who lack subspecialist access because of…”
Self-citationOktavian, P., Wungu, C. D. K., Wibisono, S., & Amin, I. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16268 · Cited by 7
“8,9 The pharmacological properties of RAI, administered subcutaneously, limit the ability of AID systems to respond to abrupt changes in glucose levels.”
Berget, C., Annan, F., Biester, T., Choudhary, P., Forlenza, G. P., Peters, A. L., Renard, É., & Deiss, D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16321 · Cited by 9
Self-citationHybrid Closed Loop in Adolescents and Young Adults Living with Type 1 Diabetes: A Real-World Study
Ung, M., Penfornis, A., Valentim, C., Franc, S., Amadou, C., & Eroukhmanoff, J. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0528 · Cited by 7
Turner, L. V., Sherr, J. L., Zaharieva, D. P., Baran, J., Hirsch, I. B., Bode, B. W., Brown, S. A., Bzdick, S., Church, M. M., Hansen, D. W., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0141 · Cited by 8
Self-citationBombaci, B., Calderone, M., Pisa, A. D., Rocca, M. L., Torre, A., Lombardo, F., Salzano, G., & Passanisi, S. (2025) · Medicina · doi:10.3390/medicina61091602 · Cited by 15
“These systems facilitate more consistent achievement of personalized glycemic targets, thereby reducing the daily management burden on families and caregivers and improving quality of life for children with T1D [1].”
Joubert, M., Meyer, L., Bekka, S., Rakotoarisoa, L., Scheyer, N., Dreves, B., & Guerci, B. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70122 · Cited by 9
“These recommendations represented a pragmatic and simplified adaptation of the international consensus on AID use available at the time of the study 23 and were intended to optimise glycemic control during PA in real-life conditions (Supplemental Table 1).”
Kobayati, A., Fathi, A. E., Garfield, N., Legault, L., Jafar, A., Yale, J., Tsoukas, M. A., & Haidar, A. (2025) · Nature Communications · doi:10.1038/s41467-025-63671-0 · Cited by 11
Self-citationHwang, M., Rachim, V. P., Yoo, J., Lee, Y., & Park, S. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01994-4 · Cited by 13
“First, correction boluses are frequently required, even after the administration of a meal bolus 4 .”
Renard, É., Tubiana‐Rufi, N., Chaillous, L., Bonnemaison, É., Hanaire, H. P., Bismuth, É., Joubert, M., Coutant, R., Schaepelynck, P., Beltrand, J., et al. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.04.002 · Cited by 13
Lundemose, S. B., McCarthy, O. M., Christensen, M. B., Laugesen, C., Bracken, R. M., Holst, J. J., Ranjan, A. G., & Nørgaard, K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16103 · Cited by 8
Self-citationBismuth, É., Joubert, M., Renard, É., Tubiana‐Rufi, N., Chaillous, L., Bonnemaison, É., Hanaire, H. P., Coutant, R., Schaepelynck, P., Beltrand, J., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101637 · Cited by 10
Passanisi, S., Berg, A. K., Chobot, A. P., Santos, T. J. D., Piona, C. A., Messer, L. H., Lombardo, F., & ISPAD Jenious Group (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231206155 · Cited by 8
Self-citationLai, S. T., Styles, S. E., Boucsein, A., Zhou, Y., Michaels, V. R., Jefferies, C., Wilshire, E., de Bock, M. I., & Wheeler, B. J. (2024) · Diabetic Medicine · doi:10.1111/dme.15448 · Cited by 7
The DERMIS Study: Methodologies, Results, and Implications for the Future
Hirsch, I. B., Khakpour, D., Joseph, J. I., Shinohara, M. M., Wang, R. K., Klueh, U., Kreutzner, D., Riveline, J., Jacquemier, P., Maier, L. E., et al. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241298005 · Cited by 7
Self-citationDovč, K., Spanbauer, C., Chiarle, E., Bratina, N., Fröhlich-Reiterer, E. E., Potočnik, N., Zaharieva, D. P., Hropot, T., Fritsch, M., Calhoun, P. M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16211 · Cited by 7
Self-citationDiabetes advocacy in the Asia–Pacific region
Kodani, N., Kato, A., Lee, M., Ronald, C. W., Sabidi, A., Scibilia, R., Zhou, Z., & Jenkins, A. J. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70084 · Cited by 7
Pavlou, P., Reddy, M., Avari, P., Leelarathna, L., Tan, R., Chowdhury, T. A., Hyslop, R., Hussain, S., Johnston, T., & Karalliedde, J. J. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70141 · Cited by 7
“Glucose variability is de fi ned as the coef fi cient of variation, calculated by dividing the standard deviation of sensor glucose values by the mean of sensor glucose values during the observation period 7 .”
Self-citationAutomated Insulin Delivery for Type 1 Diabetes: Present and Future
Akcan, T., Lee, M. Y., Needleman, L., & Lal, R. (2025) · Diabetes Spectrum · doi:10.2337/dsi25-0003 · Cited by 6
Self-citationLundemose, S. B., Ranjan, A. G., Nørgaard, O., Suvitaival, T., & Nørgaard, K. (2025) · Diabetes Care · doi:10.2337/dc25-0702 · Cited by 6
Self-citationHussain, S., Saltik, A. Z. O., Yu, J. J., de Portu, S., Pollock, R. F., Pöhlmann, J., & Cohen, O. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251380593 · Cited by 8
Ruddiman, K. R., Bartfield, J. K., & Hirsch, I. B. (2025) · Obesity · doi:10.1002/oby.70033 · Cited by 10
Self-citationResi, V., Bianchi, C., Burlina, S., Grancini, V., Manicardi, E., Masulli, M., Scarpitta, A. M., Sorice, G. P., & Fresa, R. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02592-2 · Cited by 7
Recent Advances of Nanomaterials in Electrochemical Enzyme‐Free Glucose Sensors
Yu, Y., Sang, M., & Liu, Y. (2025) · Food Bioengineering · doi:10.1002/fbe2.70031 · Cited by 6
Joubert, M., Dreves, B., Arnould, T., Soussi, A., Nars, G., Canet, C., Grandhaie, A., Hurel, C., Louis, A., Louvet, P., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70396 · Cited by 6
Does Insulin Delivery Technology Change Our Relationship with Foods? A Scoping Review
South, C. A., Talbo, M. K., Roy‐Fleming, A., Peters, T. M., Nielsen, D. E., Iceta, S., & Brazeau, A. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0382 · Cited by 7
Type 1 diabetes mellitus: a brave new world
Martens, P.-J., & Mathieu, C. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00936-y · Cited by 6
“Now, artificial intelligence is also entering the arena, with hybrid closed-loop or automated insulin delivery (AID) systems demonstrating a marked effect on glucose control and on quality of life 1 .”
Tatulashvili, S., Dreves, B., Meyer, L., Cosson, E., & Joubert, M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111592 · Cited by 8
Nutritional Management of Athletes with Type 1 Diabetes: A Narrative Review
Cavallo, M., Fano, M. D., Barana, L., Dozzani, I., Bianchini, E., Pellegrino, M., Cisternino, L., Migliarelli, S., Giulietti, C., Pippi, R., et al. (2024) · Nutrients · doi:10.3390/nu16060907 · Cited by 10
“For CSII users, insulin infusion rates should be reduced between 50% and 100% one to two hours before EXE, as circulating insulin levels at the start of EXE are a predictor of hypoglycemia during EXE [57].”
BackgroundInfluentialOlid-Cárdenas, M. J., Jurado, A. L., Monroy, G., Gómez‐Perea, A., Cano-Ortíz, A., Jiménez, A. B. A., García-Ruiz, A., Jiménez-Cuenca, P., César, M. J. P., & Gea, I. L. (2024) · Nutrients · doi:10.3390/nu16142210 · Cited by 9
Saeed, Z. I., Aktürk, H. K., Aleppo, G., Kruger, D. F., Levy, C. J., Mader, J. K., Sherr, J. L., & Shah, V. N. (2024) · Clinical Diabetes · doi:10.2337/cd24-0067 · Cited by 8
Self-citationNigi, L., Batzibal, M. S., Cataldo, D., & Dotta, F. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01656-w · Cited by 7
Molfetta, S. D., Rossi, A., Gesuita, R., Faragalli, A., Cutruzzolà, A., Irace, C., Minuto, N., Pitocco, D., Cardella, F., Arnaldi, C., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02381-3 · Cited by 7
Monnier, L., Colette, C., Renard, É., Benhamou, P., Aouinti, S., Molinari, N., & Owens, D. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101589 · Cited by 8
Brown, S. A., Laffel, L. M., Aktürk, H. K., Forlenza, G. P., Shah, V. N., Wadwa, R. P., Cobry, E. C., ISGANAITIS, E. M., Schoelwer, M. J., Lu, V. M., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0501 · Cited by 6
“…the bolus size by half if the meal bolus is delayed 30 – 60 min, or only giving only a correction dose if > 60 min has elapsed from the start of a meal as recommended by the ATTD 2022 guidance, 15 the late bolus feature offered an automated calculation to implement similar advice for the user.”
Self-citationTransitioning between automated insulin delivery systems: A focus on personalisation
Beato-Víbora, P. I., Chico, A. I., Moreno-Fernández, J., Azriel, S., Nattero‐Chávez, L., Mora, M. R. V., Alonso-Carril, N., Simó‐Servat, O., Aguilera, E., Reyes, L., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112070 · Cited by 9
“…the selection of a particular AID system for each individual is pivotal to optimising outcomes and international guidelines advise that the choice of the device should be based on individual circumstances, preferences, and needs, although no specific recommendations have been published [21,32,33].”
Closed-loop Artificial Pancreas Development: A Review
Glumčević, S., Mašetić, Z., & Viteškić, B. (2023) · International Convention on Information and Communication Technology, Electronics and Microelectronics · doi:10.23919/mipro57284.2023.10159633 · Cited by 6
Mesa, A., Beneyto, A., José, J., Viaplana, J., Bondía, J., Vehí, J., Conget, I., & Giménez, M. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110956 · Cited by 7
Digital Technology for Diabetes
Kinny‐Köster, B., Michalski, C. W., & Loos, M. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2315000 · Cited by 6
Diabetes Technology Use in Special Populations: A Narrative Review of Psychosocial Factors
Hughes, M. S., Aleppo, G., Bally, L., Batista, A. F. M. B., Brown, S. A., Faulds, E. R., Gonder-Frederick, L. A., Isaacs, D. M., Kahkoska, A. R., Ortega, J., et al. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241296853 · Cited by 6
Self-citationHu, Z.-M., Luo, Y., Junaid, M., Xu, R., Chen, Y.-Q., Yao, J., Ni, R.-H., Zhu, T., Zhang, H., Ding, H., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.169527 · Cited by 5
Digital management of diabetes global research trends: a bibliometric study
Zhu, S., Bian, H., Zhan, J., Ni, L., Huo, L., & Hu, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1620307 · Cited by 7
Rethinking control‐ IQ + technology: Simple strategies for easy optimization
Shah, V. N., Choudhary, P., Halperin, I. J., Rabbone, I., Zaharieva, D. P., & Messer, L. H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70500 · Cited by 5
“6,28,45 Though carbohydrate counting and pre-meal bolus have been associated with better glycaemic outcomes with the use of AID systems, 46 nearly 1 in 10 users of Control-IQ have gone a week or longer without delivering a bolus.”
Self-citationChowdhury, S., Sarkar, S., Das, A., Kar, K., & Chakraborty, P. (2026) · Next Bioengineering · doi:10.1016/j.nxbio.2026.100027 · Cited by 9
Pei, Y., Ke, W., Lü, J., Lin, Y., Zhang, Z., Peng, Y., Bi, Y., Li, Y., Hou, J., Zhang, X., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0234 · Cited by 5
Schütz, A. K., Rami-Merhar, B. M., Schütz-Fuhrmann, I., Blauensteiner, N., Baumann, P. M., Pöttler, T., & Mader, J. K. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241230106 · Cited by 6
“6,8,9 With the approval of the first commercial AID system (MiniMed 670G system, Medtronic, Northridge, CA, USA) in 2016, the first AID system was introduced to the market and the clinical practice in 2017.”
Izquierdo, F. J. E., García, M. J. A., Vaquero, A. A. C., Gamero, J. A. L., Gómez-Turégano, P., Andrada, M. L., Pearson, A. C., & Figueredo, R. J. G. (2024) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2024.03.019 · Cited by 5
Gallen, G., Alice, R., Alonso-Carril, N., Arbeli, S., Bahon, V., Vanessa, B., Kerstin, E., Gulotta, F., Audrey, H., Jolley, A., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02388-w · Cited by 7
Self-citationLebbar, M., Bonhoure, A., RABASA-LHORET, R. P. R., & Wu, Z. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.12.004 · Cited by 5
Papa, G. F. S., Cannarella, R., Gusmano, C., Finocchiaro, C., Anzaldi, M., Gruttadauria, G., Patti, L., Presti, D. L., Calabrisotto, S. S., Condorelli, R. A., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112476 · Cited by 5
Metadata
- Authors
- Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., Amiel, S. A., Bally, L., Beck, R. W., Biester, S., Biester, T., Blanchette, J. E., Bosi, E., Boughton, C. K., Breton, M. D., Brown, S. A., Buckingham, B. A., Cai, A., Carlson, A. L., Castle, J. R., Choudhary, P., Close, K. L., Cobelli, C., Criego, A. B., Davis, E., de Beaufort, C., de Bock, M. I., DeSalvo, D. J., DeVries, J. H., Dovc, K., Doyle, F. J., Ekhlaspour, L., Shvalb, N. F., Forlenza, G. P., Gallen, G., Garg, S. K., Gershenoff, D. C., Gonder-Frederick, L. A., Haidar, A., Hartnell, S., Heinemann, L., Heller, S., Hirsch, I. B., Hood, K. K., Isaacs, D., Klonoff, D. C., Kordonouri, O., Kowalski, A., Laffel, L., Lawton, J., Lal, R. A., Leelarathna, L., Maahs, D. M., Murphy, H. R., Nørgaard, K., O’Neal, D., Oser, S., Oser, T., Renard, E., Riddell, M. C., Rodbard, D., Russell, S. J., Schatz, D. A., Shah, V. N., Sherr, J. L., Simonson, G. D., Wadwa, R. P., Ward, C., Weinzimer, S. A., Wilmot, E. G., & Battelino, T.
- Affiliations
- Tel Aviv University (IL)
- HealthPartners (US)
- Southern Health NHS Foundation Trust (GB)
- Kinderkrankenhaus auf der Bult (DE)
- University of Cambridge (GB)
- University of Virginia (US)
- University of Colorado Anschutz (US)
- CGParkin Communications, Inc. , Henderson, NV , USA
- Joslin Diabetes Center (US)
- King's College London (GB)
- University of Bern (CH)
- Jaeb Center for Health Research (US)
- University of Utah (US)
- Vita-Salute San Raffaele University (IT)
- Stanford Medicine (US)
- Close Concerns (United States) (US)
- Oregon Health & Science University (US)
- University of Leicester (GB)
- University of Padua (IT)
- The Kids Research Institute Australia (AU)
- Diabetes & Endocrine Care Clinique Pédiatrique DECCP/Centre Hospitalier Luxembourg, and Faculty of Sciences, Technology and Medicine, University of Luxembourg, Esch sur Alzette, GD Luxembourg/Department of Paediatrics, UZ-VUB , Brussels , Belgium
- Department of Paediatrics, University of Otago , Christchurch , New Zealand
- Baylor College of Medicine (US)
- Amsterdam University Medical Centers (NL)
- Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, UMC - University Children’s Hospital, Ljubljana, Slovenia, and Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia
- Harvard University (US)
- Lucile Packard Children's Hospital (US)
- The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel , 49202 Petah Tikva , Israel
- McGill University (CA)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Science Consulting in Diabetes GmbH , Kaarst , Germany
- University of Sheffield (GB)
- University of Washington (US)
- Cleveland Clinic (US)
- Diabetes Research Institute, Mills-Peninsula Medical Center , San Mateo, CA 94010 , USA
- Breakthrough T1D (US)
- University of Edinburgh (GB)
- University of Manchester (GB)
- University of East Anglia (GB)
- University of Copenhagen (DK)
- Department of Medicine and Department of Endocrinology, St Vincent’s Hospital Melbourne, University of Melbourne , Melbourne , Australia
- Department of Endocrinology, Diabetes, Nutrition, Montpellier University Hospital, and Institute of Functional Genomics, University of Montpellier, CNRS, INSERM , Montpellier , France
- York University (CA)
- Biomedical Informatics Consultants LLC , Potomac, MD , USA
- University of Florida (US)
- Yale University (US)
- University of Nottingham (GB)
- University of Ljubljana (SI)
- Corresponding author
- Phillip, Moshe
- Nimri, Revital
- ORCID
- Phillip, Moshe
- Nimri, Revital
- Bergenstal, Richard M
- Barnard-Kelly, Katharine
- Danne, Thomas
- Hovorka, Roman
- Kovatchev, Boris P
- Messer, Laurel H
- Parkin, Christopher G
- Amiel, Stephanie A
- Bally, Lia
- Beck, Roy W
- Biester, Torben
- Blanchette, Julia E
- Bosi, Emanuele
- Boughton, Charlotte K
- Breton, Marc D
- Brown, Sue A
- Buckingham, Bruce A
- Carlson, Anders L
- Castle, Jessica R
- Choudhary, Pratik
- Close, Kelly L
- Cobelli, Claudio
- Criego, Amy B
- Davis, Elizabeth
- de Beaufort, Carine
- de Bock, Martin I
- DeSalvo, Daniel J
- DeVries, J Hans
- Dovc, Klemen
- Doyle, Francis J
- Ekhlaspour, Laya
- Shvalb, Naama Fisch
- Forlenza, Gregory P
- Gallen, Geraldine
- Garg, Satish K
- Gonder-Frederick, Linda A
- Haidar, Ahmad
- Hartnell, Sara
- Heinemann, Lutz
- Heller, Simon
- Hirsch, Irl B
- Hood, Korey K
- Isaacs, Diana
- Klonoff, David C
- Kordonouri, Olga
- Kowalski, Aaron
- Laffel, Lori
- Lawton, Julia
- Lal, Rayhan A
- Leelarathna, Lalantha
- Maahs, David M
- Murphy, Helen R
- Nørgaard, Kirsten
- Oser, Sean
- Oser, Tamara
- Renard, Eric
- Riddell, Michael C
- Rodbard, David
- Russell, Steven J
- Schatz, Desmond A
- Shah, Viral N
- Sherr, Jennifer L
- Simonson, Gregg D
- Wadwa, R Paul
- Weinzimer, Stuart A
- Wilmot, Emma G
- Battelino, Tadej
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2022-09-06
- Volume
- 44
- Issue
- 2
- Pages
- 254-280
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC9985411
- OpenAlex
- W4294783598
- Semantic Scholar
- 28646f57b5b3cbcfac8f10ea51308aadbf9e4f00
- Cited by
- 443
- References
- 144
- Citations by year
- 2026: 102 · 2025: 121 · 2024: 141 · 2023: 76 · 2022: 3
- FWCI
- 63.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Repository@Nottingham (University of Nottingham) (publishedVersion, cc-by-nc-nd)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Pure Amsterdam UMC (acceptedVersion, cc-by)
- HAL (submittedVersion, cc-by-nc-nd)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by-nc-nd)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by-nc-nd)
- Figshare (submittedVersion, cc-by-nc-nd)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Open Access CRIS of the University of Bern
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Virginia
- Bigfoot Biomedical
- Insulet Corporation
- MannKind Corporation
- Dexcom
- Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
- Cardinal Health
- Tandem Diabetes Care
- National Institute for Health and Care Research (16/35/01, CL-2020-14-801)
- Novo Nordisk
- Roche Diabetes Care
- National Institutes of Health (UL1TR001863)
- University of Colorado Denver
- Abbott Diabetes Care
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942, K23DK122017, R01DK129553, P30DK045735)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- artificial pancreas, diabetes management, glycemic control, hypoglycemia risk, insulin pump therapy, continuous glucose monitoring, eligibility criteria, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Humans, Hypoglycemic Agents, Insulin, Blood Glucose Self-Monitoring, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.